INTRODUCTION AND OBJECTIVES: Wilms tumor (WT), a pediatric cancer also known as nephroblastoma, accounts for 95% of renal malignancies in children. Currently little is known of WT formation, and less than half of these tumors are diagnosed at Stage 1 due to their asymptomatic nature. The presence of nephron progenitors (NP) characterized by the expression of CITED1 and/or SIX2 determine the aggressive state of the tumor. However, due to past inability to isolate live human WT CITED1 and/or SIX2 positive cells, little is known about their cell biology and involvement in tumor progression.
METHODS: To answer these questions, we used immunofluorescence to characterize WT samples and identified CITED1þ, SIX2þ and CITED1SIX2þ cells within WT samples and compared our findings with NP isolated from human fetal renal samples. In addition, using our established Smartflare isolation methods, we obtained live CITED1SIX2 positive cells from WT samples, isolated RNA and performed RNA-Seq.
RESULTS: We confirm the expression of CITED1 and SIX2 positive cells within the WT samples, and for the first time we also established the existence of a side population expressing both CITED1 and SIX2, as observed in the true NP within the human fetal kidney at week gestation 16. Further characterization of the WT also identified the absence of mature renal cell markers such as Nephrin and Aquaporin along with the absence of renal developmental markers such as Calbindin and LEF1. However, unlike NP from fetal kidney, some WT cells express NPHS2 and WT1 similarly to developing structure such as the renal vesicle, C-shaped bodies, S-shaped bodies, and glomeruli. Using Smartflare technology we have identified on average 6.7% SIX2þ, 0.1% CITED1þ, and 12.43% CITED1SIX2þ cells, while human fetal samples express .16% of CITED1SIX2þ, 19.8% of SIX2þ and hardly any CITED1þ cells. Our RNA-Seq analysis identified different pathways expressed between NP isolated from fetal kidney and WT, specifically in relation to their cell cycle and cell cycle regulators.
CONCLUSIONS: This work suggests that we can identify and select for the first time CITED1SIX2 cell present within the WT. RNASeq data showed the presence of mechanisms essential for tumor formation. The discovery of this mechanism can help the development of new strategies aimed at halting tumor progression.
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INTRODUCTION AND OBJECTIVES: von-Hippel Lindau (VHL) disease is an autosomal dominant inherited disorder in which affected individuals develop cystic and solid growth in multiple organs. While VHL is caused by germline alterations of the VHL gene, the manner of allelic loss is variable. Previous work has shown there may be genotype-phenotype effects in VHL, wherein the manner of alteration of VHL affects the phenotypic manifestations of the disease. We sought to characterize the genotype-phenotype alterations seen in a large cohort of patients treated at our institution.
METHODS: A prospective registry of patients with VHL treated at the National Cancer Institute was queried for germline mutation type and phenotypic manifestations. Germline mutations were categorized into missense, partial deletion, nonsense, frameshift, complete deletion, splice site alteration, amino acid insertion/deletion, or silent. The following manifestations were assessed: central nervous system (CNS) hemangioblastomas, retinal angiomas, endolymphatic sac tumor, solid kidney tumors, kidney cysts, pheochromocytoma, solid pancreatic tumors, pancreatic cysts, and epididymal cyst adenomas. Patients were excluded if neither their personal nor family genotype were known.
RESULTS: A total of 766 patients with genotype and phenotype information representing 402 VHL families were available for analysis. Table 1 demonstrates phenotypic associations by germline mutation type. The most common manifestation was CNS hemangioblastomas, with 78.9% of individuals found to be affected. Solid kidney tumors were seen in 57.3% of patients. Patients with complete deletions were at lower risk for development of several manifestations relative to the rest of the cohort, including solid kidney tumors, retinal angiomas, endolymphatic sac tumors and pheochromocytomas. Patients with missense mutations have an increased frequency of pheochromocytomas but reduced occurrence of renal tumors when compared to patients with other mutation types.
CONCLUSIONS: These data indicate that there is a genotypephenotype effect in VHL. These findings have potential implications for screening and may provide insight into disease biology. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e893
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CLEAR Also, only limited molecular information is available in CCP-RCC, which has primarily been focused on VHL alterations. In this study we aimed to better understand the mutational landscape of CCP-RCC and provide extended follow up information.
METHODS: A retrospective search of our institutional database from 1997-2017 yielded 64 cases of CCP-RCC treated by surgical resection. Follow up was obtained for all patients. 17 cases that showed classic morphology and immunoprofile of CCP-RCC were selected for molecular testing. We used the Oncomine Comprehensive Assay v3 (ThermoFisher) that covers 161 cancer-related genes including 51 fusion drivers, 91 copy number variants, 48 full-length genes and 87 hotspot mutations. HDx positive controls were used and 90% of expected variants were detected. Average read depth per sample was 1418x.
RESULTS: For the cohort of 64 CCP-RCC, the mean patient age was 60 years (range 34-82) with a 1.6:1 male:female ratio. CCP-RCC was identified in the context of end-stage renal disease in 29.7% of the cases. No recurrence or metastasis was detected in any case after a mean follow up of 57 months (range 1-240 months). In the subset of 17 CCP-RCC that underwent sequencing, seven cases (41.1%) showed no mutations in the cancer-related genes tested, eight (47.1%) cases had a single mutation, and only two (11.8%) cases had 2 mutations (Table 1) . No fusion drivers were detected.
CONCLUSIONS: All 64 patients with CCP-RCC had indolent behavior after a maximum follow up of twenty years. Targeted sequencing of 17 cases showed recurrent somatic mutations in ARID1A, NOTCH3, KIT and TSC1 in subsets of tumors. Nearly half of the cases had no detectable mutation at all. This study is the largest and most comprehensive molecular characterization of CCP-RCC to date and reports the longest available follow up. Our findings support the notion that CCP-RCC harbors a unique mutational landscape and follows an indolent clinical course. METHODS: We identified patients who were clinically diagnosed as Xp11.2 translocation RCC by immunostaining positive of TFE3 from two tertiary referral hospitals. Among them, a total of 19 patients whose fresh frozen tissue and normal DNA were achieved were included in the analysis. Whole exome sequencing (WES) was performed to evaluate somatic mutations and copy-number variation (CNV). We also performed RNAseq on the TFE3-positive RCC, 7 clear cell RCC, and 4 normal kidney tissue for comparison. Fusion partners were identified and clustering analysis was done by RNAseq.
Source of
RESULTS: Mutational landscape of TFE3-positive RCC is unique by low somatic mutation rate and very rare COSMIC variants. High prevalence of CNV with loss of 3p, 6q, 9, gain of 5, 7, and 12 were most frequent. We identified NONO, RBM10, SFPQ, ASPSCR1 and PRCC as fusion partner as previously described. We could not find TFE3 fusion in 4 out of 19 patients by RNAseq, and they were older and had more mutations than the others. They were also genetically clustered with clear cell RCC. Oxidative reducatase pathway was upregulated and immune response and cell adhesion were downregulated by gene ontology results from heatmap clusters. These may promote metastasis, resistant to immunity and cell survival in poorer condition which could be potential mechanism of Xp11.2 translocation RCC aggressiveness.
CONCLUSIONS: TFE3-positive RCC showed distinctive mutation pattern with low somatic mutation and rare common driver gene. A quarter of clinically diagnosed Xp11.2 translocation RCC (4/19) did not have real gene fusion even in TFE3 overexpression. They were older and had more somatic mutations than the others. Furthermore, they were clustered with clear cell RCC.
